| Description | ALK4290 (AKST4290) is a potent and orally actively CCR3 inhibitor, compound Example 2, with a Ki of 3.2 nM for hCCR3[1]. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism[2][3]. |
| Target activity | CCR3:3.2 nM (Ki) |
| Synonyms | ALK4290 |
| molecular weight | 512.04 |
| Molecular formula | C27H34ClN5O3 |
| CAS | 1251528-23-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| References | 1. NIVENS MC, et, al. Use of ccr3-inhibitors. US20130261153A1. 2. Samanta A, te, al. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Asia Pac J Ophthalmol (Phila). May-Jun 2020; 9(3):250-259. 3. Clinical Development of AKST4290 as a Novel Parkinson’s Therapeutic |